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ABSTRACT
Introduction: Colorectal cancer (CRC) is a malignant neoplasm with major impact 
on health today. There is, however, an efficient method for prevention and screening, 
which varies in different protocols according to each institution or country. The objective 
is to evaluate the mortality rate and the economic cost of CRC in Brazil during the 
first 16 years of the 21st century.
Method: A retrospective, temporal aggregation study was conducted with an exploratory, 
documentary quantitative approach on CRC mortality from 2000 to 2016, based on the 
Mortality Information System database provided by the Brazilian Ministry of Health.
Results: In the study period, 218,000 deaths due to CRC were recorded. The CRC 
mortality rate was 6.2 (95% confidence interval, 5.59-6.81) per 100,000 population, 
with no significant difference between men and women. Of the 17 age subgroups 
analyzed, eight had a significant increase from 2000 to 2016, including all subgroups 
aged over 50 years.
Conclusion: There was an increase in mortality due to CRC in the study period.
Keywords: Mortality; colorectal cancer; Brazil
The epidemiology of colorectal cancer (CRC) varies considerably according 
to each region, but worldwide it is the second leading cause of death in women 
and the third in men1-3. In Brazil, according to the National Cancer Institute 
(Inca), CRC mortality follows the same global trend when compared to other 
neoplasms, and 2018 estimates indicate that women are more frequently 
affected than men (18,980 × 17,380 cases, respectively)4.
CRC screening methods are widely consolidated as preventive measures 
that have a significant impact on mortality, reducing it by up to 30%5. The 
gold standard for CRC screening is colonoscopy, which allows visualizing the 
entire large bowel, inspecting it with biopsy and performing polypectomy of 
adenomatous polyps6-8. However, there are other methods available such as 
high sensitivity fecal occult blood test that, if positive, require colonoscopy9.
Screening methods are aimed at detecting and removing precursor lesions 
of CRC at an early stage, before clinical presentation3,10. Significant impacts 
on CRC mortality have been observed with screening tests, especially serial 
colonoscopy every 10 years starting at age 55 years9.
Currently, in Brazil, there is a recommendation to begin population screening 
at age 50 years. There are different methods available, and colonoscopy is 
preferred because of its greater sensitivity and specificity11-13.
An epidemiological analysis of CRC in the United States has shown 
gradual declines in incidence and mortality for decades, but with significant 
reduction in the mid-2000s, especially for the adult population aged over 
65 years. Changes in lifestyle were related to a 50% drop in incidence and 
to an over 30% drop in mortality, but the use of more effective screening and 
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treatment practices also contributed to significant 
reductions after the 2000s14-17.
However, according to the American Cancer Society 
(ACS), there was a 11% increase in mortality between 
2005 and 2015 for adults aged under 55 years. 
Based on these data, ACS updated its guideline in 
2018, modifying the age to begin screening from 
50 to 45 years for CRC intermediate risk groups9.
Due to changes in CRC occurrence and mortality 
patterns in several countries, analyzing variations in 
CRC mortality over the years in Brazil is fundamental, 
as well as investigating geographical differences in 
mortality given the vastness of the Brazilian territory 
and important cultural, behavioral and economic 
differences across Brazilian regions. Another objective 
of the study is to evaluate the economic cost of CRC 
in the public health system.
METHOD
A retrospective, temporal aggregation study 
was conducted with an exploratory, quantitative 
documentary approach. CRC-related mortality 
data were collected from the Mortality Information 
System (SIM) available at the Information Technology 
Department of the Brazilian Unified Health System 
(DATASUS)18, referring to a period of 17 years (2000 
to 2016). Demographic data for each year, age group 
and sex were obtained from the Brazilian Institute of 
Geography and Statistics (IBGE)19.
The variables observed were the total number 
of deaths due to CRC, subdivided into malignant 
neoplasms of colon (ICD-10, C18), rectosigmoid 
junction (ICD-10, C19) and rectum (ICD-10, C20), 
with analysis of registries divided into the 27 Brazilian 
states and the Federal District (according to the 
IBGE). For a better analysis, the five administrative 
regions of Brazil – South, Southeast, Midwest, North 
and Northeast – were also analyzed. The data were 
divided according to year of death, sex and age 
(0-4, 5-9, 10-14, 15-19, 20-24, 25-29, 30-34, 35-39, 
40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 
75-79, 80+ years). To calculate mortality, rates were 
standardized for specific age groups. The data were 
described in calculations per 100,000 population and 
for each sex.
The SIM system consists of a free access database 
of unidentified patient information provided by the 
Brazilian Ministry of Health, with the purpose of 
allowing epidemiological analysis of reported data. 
The economic cost of CRC treatment and the average 
cost of CRC hospital admission were obtained from 
the Hospital Information System (SIH), also available 
at the DATASUS website.
Municipal distribution maps were developed using 
data from the SIM system and IBGE geographical 
distribution reports. Their correlation was analyzed 
in Tableau, version 2018.1, an interactive data 
visualization software.
The data were treated statistically and analyzed 
quantitatively in Microsoft Excel 2010 (Microsoft Corp., 
United States) and GraphPad Prism 6. For statistical 
comparisons across the years, Student’s t-test was 
used for parametric variables and Mann-Whitney 
U test for nonparametric variables. Data were also 
treated descriptively. The results were reported as 
graphs and tables for better interpretation. Values 
were considered significant if p ≤ 0.05.
RESULTS
In the study period, 218,000 deaths were due 
to CRC in Brazil, with 21.8% (62,000) described 
as rectal cancer, 64.5% (140,000) as colon cancer 
and 6.7% (14,000) as rectosigmoid junction cancer 
(Table 1). CRC mortality rate was 6.2 (95% confidence 
interval – CI, 5.59-6.81) per 100,000 population, 
and there was no significant difference in mortality 
rates between men and women (p = 0.4410).
As shown in Graph 1, the most affected age 
groups were older populations. According to the 
death registry, mean age was 67 (95% CI, 66.8-67.5) 
years for men and 67.9 (95% CI, 67.7-68.2) years 
for women (p < 0.0001) (Graph 2).
In Brazil, there was an 84.8% increase in the 
number of CRC death reports from 2000 to 2016 
(p < 0.0001), as shown in Table 2, that this increase 
was observed in four of the five Brazilian regions. 
A municipal distribution analysis (Figure 1) comparing 
the period from 2000 to 2016 visually represents the 
significant increase in CRC mortality, especially in 
the Northeast and North regions.
In eight of the 17 age subgroups analyzed, there 
was an increase in reported mortality, including 
30-34, 40-44, and all subgroups aged over 50 years. 
Increases ranged from 25% to 51% between 2000 
and 2016.
The present study also analyzed CRC treatment 
cost data provided by the Brazilian Unified Health 
System. Between 2000 and 2016, there was a 
1,100% increase in treatment cost per year, from 
R$ 15 million to R$ 180 million, with an average 
hospital cost of R$ 1,700 (Graph 3).
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Table 1: Distribution of death notification and mortality according to anatomical location of colorectal cancer per federal 
unit in Brazil.
Topography of 
colorectal cancer/
Federal Unit
Rectum Colon Rectosigmoid junction
Deaths
Mortality 
per 100,000 
population
Deaths
Mortality 
per 100,000 
population
Deaths
Mortality 
per 100,000 
population
Brasil 62,888 1.61-1.97 140,666 3.63-4.37 14,708 0.35-0.48
South 11,145 2.17-2.59 29,129 5.73-6.72 2,594 0.49-0.62
Rio Grande do Sul 4,826 2.35-2.88 15,115 7.58-8.79 1,462 0.7-0.89
Santa Catarina 1,862 1.6-1.95 4,686 4.02-4.92 479 0.36-0.55
Paraná 4,457 2.24-2.75 9,328 4.76-5.68 653 0.31-0.42
Southeast 36,544 2.03-2.42 86,588 4.83-5.7 887 0.46-0.64
São Paulo 18,281 2.41-2.77 45,345 6-6.85 4,377 0.51-0.73
Rio de Janeiro 7,905 2.71-3.18 18,477 6.32-7.43 1,451 0.45-0.63
Minas Gerais 5,179 1.34-1.75 11,383 2.98-3.81 1,586 0.4-0.55
Espírito Santo 1,070 1.55-1.95 2,484 3.47-4.66 202 0.27-0.39
Midwest 3,696 1.4-1.75 7,641 2.83-3.69 775 0.29-0.37
Mato Grosso do 
Sul 707 0.9-2.54 1,743 2.23-6.27 120 0.15-0.43
Mato Grosso 538 0.87-1.28 1,029 1.63-2.48 148 0.22-0.37
Goiás 1,690 1.48-1.87 3,006 2.56-3.41 379 0.3-0.45
Distrito Federal 761 1.59-1.98 1,863 3.88-4.86 128 0.24-0.36
North 2,035 0.63-0.91 2,441 0.79-1.06 401 0.12-0.19
Acre 62 0.39-0.65 83 0.45-0.94 20 0.05-0.28
Rondônia 221 0.61-1.01 139 0.38-0.64 70 0.18-0.33
Amazonas 575 0.81-1.15 606 0.89-1.17 96 0.1-0.23
Roraima 44 0.38-0.81 57 0.52-1.02 11 0.06-0.24
Pará 975 0.63-0.93 1,201 0.81-1.11 135 0.08-0.13
Amapá 52 0.32-0.63 61 0.34-0.76 14 0.02-0.23
Tocantins 106 0.34-0.57 294 0.96-1.57 55 0.16-0.32
Northeast 9,468 0.86-1.2 14,867 1.37-1.91 1,938 0.17-0.26
Maranhão 632 0.46-0.7 895 0.63-1.01 120 0.08-0.14
Piauí 998 1.5-2.31 759 1.08-1.82 66 0.09-0.16
Ceará 1,665 0.97-1.37 2,617 1.55-2.14 505 0.26-0.45
Rio Grande do 
Norte 634 0.99-1.35 1,027 1.57-2.23 178 0.25-0.41
Paraíba 630 0.79-1.19 862 1.04-1.67 153 0.17-0.31
Pernambuco 1,662 0.95-1.27 3,390 1.94-2.59 248 0.14-0.19
Alagoas 371 0.55-0.83 449 0.64-1.04 83 0.11-0.19
Sergipe 347 0.84-1.14 603 1.41-2.04 61 0.11-0.24
Bahia 2,529 0.86-1.19 4,265 1.47-1.99 524 0.14-0.28
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Graph 1: Distribution of reported mortality by age group.
Graph 2: Graphical analysis of notification of colorectal cancer in the first 16 years of the 21st century according to age 
and sex in Brazil.
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Table 2: Analysis of differences in reported mortality across administrative regions from 2000 to 2016 in Brazil.
Locality
2000 2016 Analysis
Mortality (per 
100,000 population)
Mortality (per 
100,000 population) Difference in % Significance
Brazil 4.24 8.32 + 96.29 p < 0.0001
South 6.63 11.79 + 77.89 p = 0.0286
Southeast 5.67 10.49 + 84.87 p = 0.159
Midwest 3.09 6.92  + 123.89 p = 0.0079
North 1.08 1.84  + 18.67 p = 0.002
Northeast 1.52 4.58 + 201.57 p < 0.0001
Figure 1: Difference in municipal distribution of death notification due to colorectal cancer from 2000 to 2016 in Brazil.
Graph 3: Distribution of costs in million reais (R$) per year 
of diagnosis and treatment of colorectal cancer in Brazil.
DISCUSSION
CRC is a malignant tumor with high incidence 
and high mortality, requiring a large volume of 
resources for its treatment. Contrasting to what 
has been observed in other countries, such as the 
United States, where there was a reduction in CRC 
incidence and mortality9,20, in Brazil there was an 
increase in the notification of deaths caused by 
CRC. Besides, elevated mortality also occurred in 
younger age groups which are not included in the 
routine population screening of the disease.
Behavioral and dietary changes associated 
with Western lifestyle have led to increased risk of 
CRC, such as smoking, excess body weight, dietary 
habits, including high alcohol and processed meat 
consumption, low fruit/vegetable, fiber and calcium 
intake, in addition to a sedentary lifestyle21-23.
Moreover, aging is the most significant risk 
factor for the development of sporadic CRC3. 
For decades in Brazil, there has been an increase in 
the longevity of the population22, which also contributes 
to this growth in CRC cases. In a historical CRC 
cohort conducted in Rio de Janeiro, men began to 
show significant increases in mortality at age 55 years 
and women at age 40 years24.
Delayed diagnosis and deficiencies in population 
screening may also have contributed to an increase 
in mortality observed in Brazil. In a study conducted in 
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New Orleans, United States, the average time between 
onset of symptoms and diagnosis of neoplasia was 
4.9 months, while in a Brazilian sample the average 
time was 9.1 ± 3.6 months. This delay between first 
clinical presentation and diagnosis is mainly due to 
administrative and structural difficulties in performing 
the exams, lack of interest or personal denial of 
health condition24.
A study conducted in the United States has shown 
that behavioral and dietary factors such as fruit and fiber 
intake and physical activity can reduce the incidence of 
CRC by up to 35%25. Also, reduced mortality in the United 
States can be partially attributed to measures of population 
screening through colonoscopy, rectosigmoidoscopy 
and fecal occult blood examination5,9.
The increase in CRC mortality in younger age 
groups found in the present study and in American 
epidemiological studies are worrisome. In addition, 
this clinical condition is symptomatic in 86% of the 
individuals diagnosed at age below 50 years, and 
this presentation is associated with more advanced 
disease and poorer prognosis3,10,25.
Elevated CRC mortality in octogenarian groups 
can be attributed to an increase in life expectancy 
of the Brazilian population. However, the increase 
observed in the age groups 45-49 years and 50-
54 years are more concerning. This trend coincides 
with that observed in other countries and has been 
the reason for reviewing the protocols of population 
screening with a reduction in the indicated age to 
begin population screening and guidance10,26.
The impact of cancer mortality is significantly higher 
in regions with a high human development index (HDI), 
accounting for 40% of global disease burden but only 
15% of the world population. While in low HDI regions, 
the impact is only 2% for 6% of the population24.
The costs of treatment and rehabilitation of patients 
with CRC are high, as they involve diagnosis, hospital 
stay, downtime, rehabilitation and clinical follow-up. 
United States estimates suggest that the individual 
cost of surgically treated patients with CRC amounts 
to nearly US$ 30,000 for treatment with 1-year follow-
up. The present study used data provided by the 
Brazilian Ministry of Health, which only accounts for 
intrahospital cost, excluding rehabilitation or clinical 
follow-up costs27.
The limitations of the present study are related 
to underreporting and qualitative issues (incorrect 
information and errors in the processing of primary 
cause codes), which may overestimate or underestimate 
mortality coefficients, reducing the accuracy of the study. 
However, in death notifications in which the underlying 
cause is a neoplasm, qualitative limitations are assumed 
to be minimized because of the evolutionary nature 
of the disease, which requires prolonged hospital 
stay and complementary confirmatory tests. In the 
DATASUS system, rectosigmoid cancer cases are 
not specified in intraperitoneal and extraperitoneal 
diseases, which is crucial for the therapeutic approach.
CONCLUSION
Mortality due to CRC in Brazil has remained 
high and has been increasing in some regions and 
in some age groups. The most commonly affected 
ages are those that should benefit the most from 
CRC screening measures. In addition, there has 
been massive investment in intrahospital treatment 
and diagnostic programs; however, such efforts 
are not accompanied by decreases in mortality, 
as observed in the United States.
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